Lupin Limited has announced the grant of 6,495 stock options to its employees under the company's established employee stock option plan. The grant was approved by the Nomination and Remuneration Committee on April 09, 2026, and disclosed to stock exchanges in compliance with regulatory requirements.

Stock Option Grant Details

The pharmaceutical company granted the options under its existing Lupin Employees Stock Option Plan 2011. All 6,495 options were allocated under this single plan structure.

Vesting and Exercise Terms

Each stock option entitles the grantee to subscribe to one equity share of the company valued at ₹2.00 upon successful vesting. The company has structured the vesting schedule to promote employee retention and long-term commitment.

The vesting schedule follows a systematic approach:

• 25% of options vest after completion of one year from grant date
• 25% vest after completion of two years
• 25% vest after completion of three years
• 25% vest after completion of four years

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was communicated to both the National Stock Exchange of India Limited and BSE Limited through official channels.

The grant represents part of Lupin's ongoing employee incentive strategy, designed to align employee interests with shareholder value creation through equity participation in the company's growth.

Lupin has officially announced that it has received regulatory approval from the US Food and Drug Administration (FDA) for its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, marking a significant development for the pharmaceutical company's US market presence.

Official Company Announcement

The company has formally announced the FDA approval, confirming its ability to commercialize this diabetes treatment combination in the United States market. The regulatory clearance enables Lupin to enter the competitive US diabetes medication segment with an extended-release combination therapy that includes two established active ingredients for diabetes management.

Product Specifications

Regulatory Achievement

The FDA approval represents an important milestone in expanding the company's diabetes care portfolio in one of the world's largest pharmaceutical markets. Lupin received approval for its Abbreviated New Drug Application for multiple dosage strengths and also secured tentative approval for an additional formulation. The FDA has approved Lupin's formulation as bioequivalent to Xigduo® XR for the indications in the approved labeling.

Strategic Market Impact

This FDA approval strengthens Lupin's position in the US pharmaceutical market and demonstrates the company's capability to navigate complex regulatory processes. The approval adds to the company's growing portfolio of diabetes care products available to American healthcare providers and patients. With products distributed in over 100 markets and a strong presence across multiple therapy areas including anti-diabetic treatments, this approval further solidifies Lupin's commitment to improving patient health outcomes in the diabetes treatment segment.